Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol? by RuaƱo Gualberto, Thompson Paul D, Kane John P, Pullinger Clive R, Windemuth Andreas, Seip Richard L, Kocherla Mohan, Holford Theodore R, Wu Alan H B in Pharmacogenomics (2010).

[PMID: 20602615] PubMed


Administered at maximal dosages, the most common statins--atorvastatin, simvastatin and rosuvastatin--lower low-density lipoprotein cholesterol (LDLC) by an average of 37-57% in patients with primary hypercholesterolemia. We hypothesized novel genetic underpinnings for variation in LDLC levels in the context of statin therapy.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.